Tamoxifen and the Farnesyl Transferase Inhibitor FTI-277 Synergize to Inhibit Growth in Estrogen Receptor-Positive Breast Tumor Cell Lines
Authors:
- Michele D. VosMVMichele D. Vos
- Meredith WicklineMWMeredith Wickline
- Christine RileyCRChristine Riley
- Teresa VallecorsaTVTeresa Vallecorsa
- JoAnne ZujewskiJZJoAnne Zujewski
- Geoffrey J. ClarkGCGeoffrey J. Clark
- 1 March 2003
- journal article
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 78 (1) , 59-67
Abstract
Farnesyl transferase inhibitors (FTIs) serve to specifically inhibit farnesyl isoprenoid lipid modification of proteins. Although originally developed as anti-Ras oncoprotein drugs, it now appears that these compounds function independently of Ras. FTIs have been shown to inhibit transformation by a variety of mechanisms, including apoptosis involving cytochrome c release from mitochondria. Tamoxifen exhibits both anti-estrogenic and estrogenic properties and is widely used as an estrogen antagonist for the treatment of estrogen receptor (ER) positive human breast tumors. Tamoxifen can induce ER-dependent apoptosis in human breast tumor cells by a mechanism involving the Bcl2/mitochondrial arm of the apoptotic machinery. Since tamoxifen and FTIs may stimulate distinct components of the mitochondrial-based apoptotic machinery, we reasoned that their effects might be synergistic. Here we show that anti-estrogens and an FTI (FTI-277) synergize to inhibit cell growth and enhance cell death in ER positive, human breast tumor cell lines. However, the drugs exhibited only additive effects on an ER negative cell line. Analysis of treated ER positive T-47D cells demonstrated that a synergistic increase in apoptosis was induced, as measured by increased caspase 3 activity. Thus, tamoxifen and FTIs may synergize to promote apoptotic cell death in ER positive human breast tumor cells.Keywords
This publication has 39 references indexed in Scilit:
- Differential Expression and Mutation of therasFamily Genes in Human Breast CancerBiochemical and Biophysical Research Communications, 1998
- Loss of oncogenic ras expression does not correlate with loss of tumorigenicity in human cells.Proceedings of the National Academy of Sciences, 1996
- Tissue-specific actions of antioestrogensMutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 1995
- Aberrant function of the Ras signal transduction pathway in human breast cancerBreast Cancer Research and Treatment, 1995
- Farnesyltransferase inhibition causes morphological reversion of ras-transformed cells by a complex mechanism that involves regulation of the actin cytoskeleton.Molecular and Cellular Biology, 1994
- Farnesyltransferase inhibitors: Ras research yields a potential cancer therapeuticCell, 1994
- Altered Growth of Human Colon Cancer Cell Lines Disrupted at Activated Ki- rasScience, 1993
- Oncogenic Activation of Ras Proteins1993
- Isoprenoid addition to Ras protein is the critical modification for its membrane association and transforming activity.Proceedings of the National Academy of Sciences, 1992
- Lipid modifications and function of the ras superfamily of proteinsBiochemical Society Transactions, 1992